Login to Your Account

Positive Tadalafil Data In BPH Starts Phase III Plans For ICOS

By Karen Pihl-Carey

Thursday, October 13, 2005
Lilly ICOS LLC plans to move tadalafil into a Phase III program for benign prostatic hyperplasia after it reached statistical significance in a Phase II proof-of-concept study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription